Study of the correlations between fractional exhaled nitric oxide in exhaled breath and atopic status, blood eosinophils, FCER2 mutation, and asthma control in Vietnamese children

Fractional exhaled nitric oxide (FENO) is a biomarker of air/way inflammation in asthma. The measurement of FENO is utilized to assist in the diagnosis and treatment of children with asthma, especially for those treated with inhaled corticosteroids. Objectives: The aims of this study were to evaluate the correlations between FENO and atopic status, blood eosinophil levels, FCER2 mutation, and asthma control in Vietnamese children. Subjects and methods: This was a prospective and descriptive study approved by the local Ethical Board. All children with uncontrolled asthma, seen in the National Hospital of Pediatrics (Hanoi, Vietnam), were included. Exhaled breath FENO, blood eosinophils, skin prick test, total IgE, asthma control test (ACT), and FCER2 gene polymorphism were performed at inclusion. They were followed up at 3 months to evaluate clinical status, FENO levels, and ACT. Results: Forty-two children with uncontrolled asthma with a mean age of 10 +/- 3 years (6-16 years) were included. The male/female ratio was 2.5/1. The mean FENO levels were 26 +/- 25 ppb. FENO was significantly higher in patients with a positive skin prick test for respiratory allergens (P<0.05). FENO was significantly correlated with blood eosinophil levels (r=0.5217; P=0.0004). Five of the 32 subjects (15.6%) had a mutation of FCER2 gene (rs28364072 SNP). In this group, the levels of FENO were highest (37 +/- 10 ppb; P<0.05). The levels of FENO were significantly decreased after 3 months of treatment (17 +/- 8 ppb vs 26 +/- 25 ppb; P<0.05). Significant correlations between inhaled corticosteroid doses and FENO levels occurred at 1 and 3 months (r=0.415, P=0.007; r=0.396, P=0.010; respectively). There were no correlations between FENO levels, ACT, and daily use of salbutamol. After 3 months, asthma remained uncontrolled in 22.2% of children. Conclusion: The measurement of FENO levels is a useful and feasible tool to predict clinical, biological, and asthma control in Vietnamese children.

Title: 

	Study of the correlations between fractional exhaled nitric oxide in exhaled breath and atopic status, blood eosinophils, FCER2 mutation, and asthma control in Vietnamese children
Authors:	Nguyen, Thi Bich Hanh Duong, Thi Ly Huong Vu, Thi Thom Pham, Thi Hong Nhung Dinh, Long Doan
Keywords:	Nitric oxide ICS FCER2 Asthma Eosinophils FENO
Issue Date:	2016
Publisher:	DOVE MEDICAL PRESS LTD, PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
Citation:	ISIKNOWLEDGE
Abstract:	Introduction: Fractional exhaled nitric oxide (FENO) is a biomarker of air/way inflammation in asthma. The measurement of FENO is utilized to assist in the diagnosis and treatment of children with asthma, especially for those treated with inhaled corticosteroids. Objectives: The aims of this study were to evaluate the correlations between FENO and atopic status, blood eosinophil levels, FCER2 mutation, and asthma control in Vietnamese children. Subjects and methods: This was a prospective and descriptive study approved by the local Ethical Board. All children with uncontrolled asthma, seen in the National Hospital of Pediatrics (Hanoi, Vietnam), were included. Exhaled breath FENO, blood eosinophils, skin prick test, total IgE, asthma control test (ACT), and FCER2 gene polymorphism were performed at inclusion. They were followed up at 3 months to evaluate clinical status, FENO levels, and ACT. Results: Forty-two children with uncontrolled asthma with a mean age of 10 +/- 3 years (6-16 years) were included. The male/female ratio was 2.5/1. The mean FENO levels were 26 +/- 25 ppb. FENO was significantly higher in patients with a positive skin prick test for respiratory allergens (P<0.05). FENO was significantly correlated with blood eosinophil levels (r=0.5217; P=0.0004). Five of the 32 subjects (15.6%) had a mutation of FCER2 gene (rs28364072 SNP). In this group, the levels of FENO were highest (37 +/- 10 ppb; P<0.05). The levels of FENO were significantly decreased after 3 months of treatment (17 +/- 8 ppb vs 26 +/- 25 ppb; P<0.05). Significant correlations between inhaled corticosteroid doses and FENO levels occurred at 1 and 3 months (r=0.415, P=0.007; r=0.396, P=0.010; respectively). There were no correlations between FENO levels, ACT, and daily use of salbutamol. After 3 months, asthma remained uncontrolled in 22.2% of children. Conclusion: The measurement of FENO levels is a useful and feasible tool to predict clinical, biological, and asthma control in Vietnamese children.
Description:	JOURNAL OF ASTHMA AND ALLERGY Volume: 9 Pages: 163-170 ; TNS06524
URI:	http://repository.vnu.edu.vn/handle/VNU_123/29514
Appears in Collections:	Bài báo của ĐHQGHN trong Web of Science